evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

3,703 questions · 3,824 findings · 858 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 573 · 15%GRADE not reported 383 · 10%Very low 993 · 26%Low 1,062 · 27.8%Moderate 614 · 16.1%High 199 · 5.2%

Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion

Number of participants with at least 1 bleeding episode · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review

Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion

Bleeding: Number of days on which a significant bleeding event occurred3 · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review

Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion

Number of participants with severe or life‐threatening bleeding · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation

Therapeutic or non‐prophylactic platelet transfusion showed no clear difference in number of participants with severe or life‐threatening bleeding up… compared with prophylactic platelet transfusion (low certainty).

1 finding from 1 review

Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion

Mortality from all causes up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review

Therapeutic or non‐prophylactic platelet transfusion vs prophylactic platelet transfusion

Number of platelet transfusions per participant up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review

Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000)

Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder

Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in numbers of participants with at least 1 clinically significant… compared with higher transfusion threshold (20,000 or 30,000) (low certainty).

1 finding from 1 review

Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000)

Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder

Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in number of participants with WHO Grade 3 or 4 bleeding up to 30 days… compared with higher transfusion threshold (20,000 or 30,000) (low certainty).

1 finding from 1 review

Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000)

Time to first bleeding episode (days) · People with a haematological disorder

Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in time to first bleeding episode (days) compared with higher transfusion threshold (20,000 or 30,000) (low certainty).

1 finding from 1 review

Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000)

Mortality from all causes up to 30 days from study entry · People with a haematological disorder

Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in mortality from all causes up to 30 days from study entry compared with higher transfusion threshold (20,000 or 30,000) (low certainty).

1 finding from 1 review

Prophylactic platelet transfusions with low‐dose schedule vs prophylactic platelet transfusions with standard‐dose schedule

Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder

Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with prophylactic platelet transfusions with standard‐dose schedule (moderate certainty).

1 finding from 1 review

Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule

Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder

Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with WHO grade 3 or 4 bleeding up to 30 days… compared with high‐dose schedule (low certainty).

1 finding from 1 review

Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule

Mortality from all causes up to 30 days from study entry · People with a haematological disorder

Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with high‐dose schedule (low certainty).

1 finding from 1 review

Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose strategies

Number of participants with at least 1 clinically significant bleeding event up to 30 days from study entry · People with a haematological disorder

Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with standard‐dose schedule (moderate certainty).

1 finding from 1 review

Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose strategies

Number of participants with WHO grade 3 or 4 bleeding up to 30 days from study entry · People with a haematological disorder

Prophylactic platelet transfusions with high‐dose schedule showed no clear difference in number of participants with WHO grade 3 or 4 bleeding up to 30 days… compared with standard‐dose schedule (low certainty).

1 finding from 1 review